311 related articles for article (PubMed ID: 24507701)
1. Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine.
Nhukeaw T; Temboot P; Hansongnern K; Ratanaphan A
BMC Cancer; 2014 Feb; 14():73. PubMed ID: 24507701
[TBL] [Abstract][Full Text] [Related]
2. Differential Cytotoxicity, Cellular Uptake, Apoptosis and Inhibition of BRCA1 Expression of BRCA1-Defective and Sporadic Breast Cancer Cells Induced by an Anticancer Ruthenium(II)-Arene Compound, RAPTA-EA1.
Ratanaphan A; Nhukeaw T; Hongthong K; Dyson PJ
Anticancer Agents Med Chem; 2017; 17(2):212-220. PubMed ID: 27039925
[TBL] [Abstract][Full Text] [Related]
3. Cellular responses of BRCA1-defective HCC1937 breast cancer cells induced by the antimetastasis ruthenium(II) arene compound RAPTA-T.
Nhukeaw T; Hongthong K; Dyson PJ; Ratanaphan A
Apoptosis; 2019 Aug; 24(7-8):612-622. PubMed ID: 31016421
[TBL] [Abstract][Full Text] [Related]
4. The trans-[Ru(PPh
Becceneri AB; Popolin CP; Plutin AM; Maistro EL; Castellano EE; Batista AA; Cominetti MR
J Inorg Biochem; 2018 Sep; 186():70-84. PubMed ID: 29857173
[TBL] [Abstract][Full Text] [Related]
5. BRCA1-Associated Triple-Negative Breast Cancer and Potential Treatment for Ruthenium-Based Compounds.
Hongthong K; Ratanaphan A
Curr Cancer Drug Targets; 2016; 16(7):606-17. PubMed ID: 26845433
[TBL] [Abstract][Full Text] [Related]
6. A novel ruthenium(ii) gallic acid complex disrupts the actin cytoskeleton and inhibits migration, invasion and adhesion of triple negative breast tumor cells.
Graminha AE; Honorato J; Correa RS; Cominetti MR; Menezes ACS; Batista AA
Dalton Trans; 2021 Jan; 50(1):323-335. PubMed ID: 33305766
[TBL] [Abstract][Full Text] [Related]
7. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells.
Pracharova J; Novohradsky V; Kostrhunova H; Štarha P; Trávníček Z; Kasparkova J; Brabec V
Dalton Trans; 2018 Sep; 47(35):12197-12208. PubMed ID: 30112527
[TBL] [Abstract][Full Text] [Related]
8. The anti-cancer effect of series of strained photoactivatable Ru(II) polypyridyl complexes on non-small-cell lung cancer and triple negative breast cancer cells.
Fayad C; Audi H; Khnayzer RS; Daher CF
J Biol Inorg Chem; 2021 Feb; 26(1):43-55. PubMed ID: 33221954
[TBL] [Abstract][Full Text] [Related]
9. E3 ubiquitin ligase CHIP attenuates cellular proliferation and invasion abilities in triple-negative breast cancer cells.
Xu J; Wang H; Li W; Liu K; Zhang T; He Z; Guo F
Clin Exp Med; 2020 Feb; 20(1):109-119. PubMed ID: 31845129
[TBL] [Abstract][Full Text] [Related]
10. Triptolide Decreases Cell Proliferation and Induces Cell Death in Triple Negative MDA-MB-231 Breast Cancer Cells.
Varghese E; Samuel SM; Varghese S; Cheema S; Mamtani R; Büsselberg D
Biomolecules; 2018 Dec; 8(4):. PubMed ID: 30563138
[TBL] [Abstract][Full Text] [Related]
11. Antitumor Effects of Ir(III)-2
Panchangam RL; Rao RN; Balamurali MM; Hingamire TB; Shanmugam D; Manickam V; Chanda K
Inorg Chem; 2021 Dec; 60(23):17593-17607. PubMed ID: 34767343
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells.
Popolin CP; Reis JPB; Becceneri AB; Graminha AE; Almeida MAP; Corrêa RS; Colina-Vegas LA; Ellena J; Batista AA; Cominetti MR
PLoS One; 2017; 12(9):e0183275. PubMed ID: 28898246
[TBL] [Abstract][Full Text] [Related]
13. Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways.
Bai X; Ali A; Lv Z; Wang N; Zhao X; Hao H; Zhang Y; Rahman FU
Eur J Med Chem; 2021 Nov; 224():113689. PubMed ID: 34293698
[TBL] [Abstract][Full Text] [Related]
14. Ru(II)-Naphthoquinone complexes with high selectivity for triple-negative breast cancer.
Oliveira KM; Peterson EJ; Carroccia MC; Cominetti MR; Deflon VM; Farrell NP; Batista AA; Correa RS
Dalton Trans; 2020 Nov; 49(45):16193-16203. PubMed ID: 32329497
[TBL] [Abstract][Full Text] [Related]
15. Anticancer Effects of Fucoxanthin through Cell Cycle Arrest, Apoptosis Induction, and Angiogenesis Inhibition in Triple-Negative Breast Cancer Cells.
Ahmed SA; Mendonca P; Messeha SS; Soliman KFA
Molecules; 2023 Sep; 28(18):. PubMed ID: 37764312
[TBL] [Abstract][Full Text] [Related]
16. Rationally Designed Ruthenium Complexes for Breast Cancer Therapy.
Golbaghi G; Castonguay A
Molecules; 2020 Jan; 25(2):. PubMed ID: 31936496
[TBL] [Abstract][Full Text] [Related]
17. miR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cells.
Crippa E; Folini M; Pennati M; Zaffaroni N; Pierotti MA; Gariboldi M
Oncotarget; 2016 Apr; 7(14):18594-604. PubMed ID: 26919240
[TBL] [Abstract][Full Text] [Related]
18. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs.
Atipairin A; Canyuk B; Ratanaphan A
Breast Cancer Res Treat; 2011 Feb; 126(1):203-9. PubMed ID: 20878461
[TBL] [Abstract][Full Text] [Related]
19. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
Pharm Res; 2018 Sep; 35(11):218. PubMed ID: 30255456
[TBL] [Abstract][Full Text] [Related]
20. Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.
Andres JL; Fan S; Turkel GJ; Wang JA; Twu NF; Yuan RQ; Lamszus K; Goldberg ID; Rosen EM
Oncogene; 1998 Apr; 16(17):2229-41. PubMed ID: 9619832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
